Dedicated to advancing healthcare, Cambridge-1 is a $100m (£74m) investment by Nvidia. Its first projects with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs, and improving the accuracy of finding disease-causing variations in human genomes.
“Cambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life’s work on the UK’s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the UK,” said Jensen Huang, founder, and CEO of Nvidia. “The discoveries developed on Cambridge-1 will take shape in the UK, but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.”
David Hogan, vice president enterprise EMEA at Nvidia, added...